Drug firm Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator for Amantadine Hydrochloride tablets, used for treatment ofinfluenza A virus.
The approved product is therapeutically equivalent to the reference listed drug product Symmetrel tablets of Endo Pharmaceuticals, Inc.
In a regulatory filing, Alembic Pharmaceuticals said "it has received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Amantadine Hydrochloride tablets in the strength of 100 mg".
Amantadine Hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
Quoting IQVIA data, Alembic Pharma saidAmantadine Hydrochloride Tablets, 100 mg have an estimated market size of USD 13 million for twelve months ending June, 2020.
IQVIA is an American multi-national company serving the combined industries of health information technology and clinical research.
Alembic now has a total of 132 ANDA approvals (114 final approvals and 18 tentative approvals) from USFDA.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU